TY - JOUR
T1 - Rapidly progressive, infantile lysosomal acid lipase deficiency
T2 - Prevalence in the Mizrahi Jewish population
AU - Bernstein, Donna L.
AU - Peter, Inga
AU - Desnick, Robert J.
N1 - Publisher Copyright:
© 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
PY - 2025/9/1
Y1 - 2025/9/1
N2 - Purpose: This study was designed to more accurately estimate the prevalence of severe, infantile onset, rapidly progressive lysosomal acid lipase deficiency (LALD), an autosomal recessive disorder caused by the homoallelic LIPA gene variant, c.260G>T; p.G87V in patients of Mizrahi Jewish ancestry. The previous estimates of LALD prevalence in Middle Eastern and Mizrahi Jewish populations, ranging from 1 in 12,100 to 1 in 4200, were based on historic, observational case reports and a population genetic screening of 165 Middle Eastern individuals and 162 Mizrahi Jews living in Southern California. Methods: Carrier screening of 549 Mizrahi Jewish individuals for the c.260G>T; p.G87V LIPA variant and the common, c.894G>A; p.E8SJM-1LIPA variant, was carried out to determine their allele frequencies and expected prevalence of LALD in a larger Mizrahi population. Results: This larger population screening study revealed a LIPA p.G87V Mizrahi founder variant allele frequency of 1 in 52.2, conferring a carrier frequency of 1 in 26.1. Therefore, the occurrence of infantile LALD was estimated to be one in 2724.8 Mizrahi Jewish conceptions in Southern California. Conclusion: The present, larger study found the prevalence of rapidly progressive, infantile LALD disease was ∼35 % greater than the previous prevalence estimate in the major U.S. Mizrahi Jewish population.
AB - Purpose: This study was designed to more accurately estimate the prevalence of severe, infantile onset, rapidly progressive lysosomal acid lipase deficiency (LALD), an autosomal recessive disorder caused by the homoallelic LIPA gene variant, c.260G>T; p.G87V in patients of Mizrahi Jewish ancestry. The previous estimates of LALD prevalence in Middle Eastern and Mizrahi Jewish populations, ranging from 1 in 12,100 to 1 in 4200, were based on historic, observational case reports and a population genetic screening of 165 Middle Eastern individuals and 162 Mizrahi Jews living in Southern California. Methods: Carrier screening of 549 Mizrahi Jewish individuals for the c.260G>T; p.G87V LIPA variant and the common, c.894G>A; p.E8SJM-1LIPA variant, was carried out to determine their allele frequencies and expected prevalence of LALD in a larger Mizrahi population. Results: This larger population screening study revealed a LIPA p.G87V Mizrahi founder variant allele frequency of 1 in 52.2, conferring a carrier frequency of 1 in 26.1. Therefore, the occurrence of infantile LALD was estimated to be one in 2724.8 Mizrahi Jewish conceptions in Southern California. Conclusion: The present, larger study found the prevalence of rapidly progressive, infantile LALD disease was ∼35 % greater than the previous prevalence estimate in the major U.S. Mizrahi Jewish population.
KW - Adrenal calcification
KW - Enzyme replacement therapy
KW - Hemophagocytic lymphohistiocytosis (HLH)
KW - Lysosomal acid lipase deficiency
KW - Persian Jewish
KW - Wolman disease
UR - https://www.scopus.com/pages/publications/105017825577
U2 - 10.1016/j.ymgme.2025.109233
DO - 10.1016/j.ymgme.2025.109233
M3 - Article
C2 - 41005123
AN - SCOPUS:105017825577
SN - 1096-7192
VL - 146
JO - Molecular Genetics and Metabolism
JF - Molecular Genetics and Metabolism
IS - 1-2
M1 - 109233
ER -